세계 천연두(Mpox) 시장 규모는 2023년 1억 8,590만 달러에서 2031년 4억 816만 달러에 달할 것으로 예상되며, 예측 기간인 22024-2031년간 연평균 10.33% 성장할 것으로 예상됩니다. 천연두의 유병률 증가, 진단 기술의 발전, 공중 보건에 대한 인식, 천연두 백신 및 치료법 개발에 대한 투자자들의 관심 증가로 인해 천연두 시장 수요는 예측 기간 동안 크게 증가할 것으로 예상됩니다.
엠톡스는 오르소폭스 바이러스 속 바이러스 감염으로 피부 발진, 점막 병변, 발열, 두통, 근육통, 피로감, 림프절 부종 등의 증상이 2-4주 동안 지속되는 바이러스 감염입니다. 집단 발병과 공중보건 프로그램에 대한 인식이 높아짐에 따라 진단, 치료 및 예방책에 대한 수요가 증가하고 있습니다. 효과적인 백신의 발전과 규제 당국의 승인은 시장을 더욱 활성화시키고 질병 부담 증가로 인해 백신 캠페인의 가속화는 예측 기간 동안 시장을 발전시킬 것으로 보입니다. 예를 들어, 2023년 1월 Becton, Dickinson and Company(BD)와 Certest Biotec, S.L.은 미국 식품의약국(FDA)으로부터 VIASURE Monkeypox Virus Real-Time PCR 시약에 대한 긴급사용승인(EUA)을 획득했습니다. 획득하였습니다. 이번 EUA를 통해 적시에 천연두를 검출할 수 있게 되어 미국 내 질병 퇴치를 위한 노력을 지원할 수 있게 되었습니다.
이 보고서는 세계 천연두 시장에 대해 조사 분석했으며, 시장 규모와 예측, 시장 역학, 주요 기업 현황 등을 제공합니다.
Global monkeypox (Mpox) market is projected to witness a CAGR of 10.33% during the forecast period 2024-2031, growing from USD 185.90 million in 2023 to USD 408.16 million in 2031. The market demand for Mpox is anticipated to thrive drastically in the forecast years due to the rising prevalence of monkeypox disease, advancement in diagnostic technology, public health awareness, and the growing interest of investors in the development of monkeypox vaccines and therapeutics.
Mpox is a viral infection within the Orthopoxvirus genus, causing symptoms such as skin rash, mucosal lesions, fever, headache, muscle pain, fatigue, and swelling of the lymph nodes that last for two to four weeks. Growing awareness due to outbreaks and public health programs has increased demand for diagnostics, therapeutics, and preventive measures. Advances and regulatory approvals of effective vaccines further spur the market, and accelerated vaccine campaigns are foreseen to propel the market ahead in the forecast period due to the increasing disease burden. For instance, in January 2023, Becton, Dickinson and Company (BD) and Certest Biotec, S.L. received an Emergency Use Authorization (EUA) approval from the U.S. Food and Drug Administration (FDA) for the VIASURE Monkeypox Virus Real-Time polymerase chain reaction (PCR) reagent. The EUA allows for timely Mpox detection, supporting disease control efforts in the United States.
Increase in the Incidences of Monkeypox (Mpox) Disease
The incidence of monkeypox disease has become a terrific public health concern because recent outbreaks have occurred in areas other than the traditional endemic zones. Initially restricted to Central and West Africa, this infection has seen a rise in cases worldwide, partially due to increased human-animal contact, environmental changes, and world travel. The sharp rise in infections has incited health authorities to heighten vigilance and response efforts, thereby creating public awareness and a sense of urgency over the disease. It places an increased demand for appropriate diagnostics, vaccines, and treatments as a robust public health strategy is paramount in managing and mitigating monkeypox. This new epidemiology requires preparation in how one responds to emerging infectious diseases in an increasingly interconnected world. For instance, in August 2024, UTime Limited completed the acquisition of the Bowen Therapeutics laboratory of Bowen Therapeutics Inc. at UMASS Medical School to cater to the need for an effective monkeypox vaccine. Monkeypox, as such, is an infectious disease caused by the monkeypox virus.
Demand for Vaccines and Treatment for Monkeypox Disease to Drive Market Growth
The rising demand for vaccines and new treatments for monkeypox is mainly driven by increased awareness that the virus could spread more widely than people thought, posing risks to public health. This awareness encourages more research and development to find effective ways to prevent and treat the disease. The recent outbreaks highlighted the need for proper preventive measures and resulted in vaccination programs at governmental and health organizations. This growing urgency drives pharmaceutical companies, researchers, and public health officials to collaborate and perform research and developmental activities to deliver novel products. In general, the focus is on the accessibility of vaccines, alternatives for treatment, infection control, and preparing the world to face emerging infectious diseases with a proactive attitude toward public health challenges. In August 2024, the World Health Organization (WHO) declared Mpox as a public health emergency of international concern due to an upsurge of Mpox cases in the Democratic Republic of the Congo (DRC). To effectively tackle this situation, the United Nations International Children's Emergency Fund (UNICEF) signed an agreement with Bavarian Nordic A/S, under which the MVA-BN Mpox vaccine would be made available to 77 low and lower-middle-income countries at the lowest price in the market. Moreover, in September 2024, WHO initiated funding of USD 58.8 million to deliver treatment for controlling the outbreak of Mpox in Burundi, Central African Republic (CAR), DRC, Kenya, Rwanda, and Uganda. These countries have registered around 22,000 cases, with around 60% cases among children under 15 years old and 80% deaths among children.
North America to Dominate Monkeypox (Mpox) Market Share
North America leads the share of the monkeypox market due to several interrelated factors, such as enhanced treatment accessibility, innovation, and new product launches. According to data from the US Centers for Disease Control and Prevention, Mpox cases in the United States have surged to a rate of 511 reported cases, showing a significant increase from 300 thousand cases by March 2023. While current transmission rates remain substantially lower than the tens of thousands reported in 2022, experts warned of potential case increases due to several factors. The expiration of the public health emergency over a year ago has limited federal resources for managing the response.
Additionally, the relatively low vaccination coverage continues to leave a substantial portion of the population at risk, underscoring the urgent need to improve vaccination efforts as transmission risks rise. In April 2024, Bavarian Nordic A/S launched JYNNEOS in the United States, the only FDA-approved Mpox vaccine. The launch has marked a significant expansion of the company's activities in the highly promising North American market. Moreover, growing awareness about vaccination and the rising target patient population will further fuel the adoption of JYNNEOS in the United States. According to the data published by the Centers for Disease Control and Prevention (CDC), around two million individuals in the United States are considered eligible for vaccination against Mpox in 2024. The data further stated that 60% of this population remains completely unvaccinated, and 15% have received just one dose of the vaccine. Real-world data demonstrate protective immunity to be more robust in vaccinated individuals who received the primary series of two doses, as indicated by the CDC, than in unvaccinated or one-dose recipients.
Future Market Scenario (2024-2031F)
The future market scenario is influenced by factors that increase demand and investment, such as the growing awareness about infectious diseases. Healthcare systems are gaining a focus on preparedness for outbreaks through increased funding for research, diagnostics, and vaccines. The recent outbreaks have forced the regulatory bodies to hasten their approval processes for monkeypox treatments and vaccines, boosting market dynamics. Several studies that are undergoing clinical trials, for instance, a phase 3 study of Tecovirimat for the Mpox virus, conducted by the National Institute of Allergy and Infectious Diseases (NIAID) to assess the efficacy of Tecovirimat for the treatment of human Mpox virus disease is holding promising outcomes. Moreover, an ongoing safety study of the MVA-BN Vaccine among children between 2-12 years is being conducted by Bavarian Nordic A/S. The study aims to compare the immunogenicity and safety of the MVA-BN vaccine to prevent Mpox, Smallpox, and other Orthopoxvirus Infections. The promising outcomes from such ongoing trials are expected to expand the existing patient base and introduce newer treatment lines, boosting market growth in the forecast years.
Key Players Landscape and Outlook
Monkeypox (Mpox) market is highly dynamic, with different players such as Bavarian Nordic A/S, Emergent BioSolutions Inc., and others. Market activity in recent years includes business agreements, collaborations, and regulatory approvals of products. The market fosters several smaller players, collaborating with other players to cater to a larger market.
In September 2022, Emergent BioSolutions Inc. (Emergent) acquired global rights of Tembexa, an oral antiviral treatment for smallpox, from Chimerix, Inc. This acquisition expanded Emergent product offerings and positioned the company alongside Siga Technologies Inc.'s Tpoxx as a potential treatment for monkeypox. The U.S. Biomedical Advanced Research and Development Authority supported the deal, signing a USD 680 million contract and securing 1.7 million Tembexa courses over 10 years.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.